Original Research

DOI: 10.4244/EIJ-D-24-00156

Determinants of adverse outcomes following patent foramen ovale closure in elderly patients

Julio I. Farjat-Pasos1,2, MD, MSc; Paul Guedeney3, MD; Eric Horlick4, MD, PhD; Jeremie Abtan5, MD, PhD; Luis Nombela-Franco6, MD, PhD; Benjamin Hibbert7, MD, PhD; Lars Sondergaard8, MD, DMSc; Xavier Freixa9, MD, PhD; Jean-Bernard Masson10, MD; Ignacio Cruz-González11, MD, PhD; Rodrigo Estévez-Loureiro12, MD, PhD; Laurent Faroux13, MD, MSc; Ashish H. Shah14, MD; Lusine Abrahamyan4, MD, MPH; Jules Mesnier5, MD, PhD; Adrián Jerónimo6, MD; Omar Abdel-Razek7, MD, MSc; Troels Højsgaard Jørgensen8, MD, PhD; Mike Al Asmar10, MD; Samuel Sitbon5, MD; Mohammed Abalhassan7, MD; Mathieu Robichaud1, MD, PharmD; Christine Houde2, MD; Mélanie Côté1, MSc; Angel Chamorro15, MD, PhD; Sylvain Lanthier16, MD; Steve Verreault17, MD; Gilles Montalescot3, MD, PhD; Josep Rodés-Cabau1,2,9, MD, PhD

Abstract

BACKGROUND: Limited data are available on transcatheter patent foramen ovale (PFO) closure outcomes in the elderly.

AIMS: Through this study, we aimed to determine the incidence and predictors of adverse events (recurrent cerebrovascular events [CVE] and atrial fibrillation [AF]) post-PFO closure in older patients with cryptogenic events.

METHODS: This multicentre international study included patients over 60 years undergoing PFO closure for cryptogenic thromboembolic events. A dedicated database compiled baseline, procedural, and follow-up data. Competing risk and adjusted outcome predictor analyses were conducted.

RESULTS: A total of 689 patients were included (median age 65 years, 41.2% female, mean Risk of Paradoxical Embolism [RoPE] score 4.5). The procedural success rate was 99.4%. After a median follow-up of 2 (interquartile range 1-5) years, 66 patients (9.6%) had died. CVE and stroke rates were 1.21 and 0.55 per 100 patient-years, respectively. Diabetes (hazard ratio [HR] 3.89, 95% confidence interval [CI]: 1.67-9.07; p=0.002) and atrial septal aneurysm (ASA; HR 5.25, 95% CI: 1.56-17.62; p=0.007) increased the CVE risk. New-onset AF occurred at a rate of 3.30 per 100 patient-years, with 51.3% within one month post-procedure. Older age (HR 1.05 per year, 95% CI: 1.00-1.09; p=0.023) and the absence of hypertension (HR 2.04, 95% CI: 1.19-3.57; p=0.010) were associated with an increased risk of AF.

CONCLUSIONS: Older patients undergoing PFO closure had a relatively low rate of CVE and new-onset AF after a median follow-up of 2 years. The presence of diabetes, ASA, and a more advanced age determined an increased risk of adverse clinical events. These factors may be considered in the clinical decision-making process regarding PFO closure in this challenging population.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 16
Aug 19, 2024
Volume 20 Number 16
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV9I12A239 Apr 22, 2014
Predictors of recurrent stroke after percutaneous closure of patent foramen ovale
Rudolph V et al
free

CLINICAL RESEARCH

10.4244/EIJV10I12A257 Apr 20, 2015
Very long-term follow-up after percutaneous closure of patent foramen ovale
Eeckhout E et al
free

State-of-the-Art

10.4244/EIJ-D-23-00915 May 16, 2025
Treatment of patent foramen ovale
Pristipino C et al
free

CLINICAL RESEARCH

10.4244/EIJ-D-17-00061 Sep 20, 2017
Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale
Susuri N et al
free
Trending articles
310.18

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
72.85

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved